Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 8/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15223713 | 0.86 | GLS (0.46) | GLSDGAT1 | |
| SCHEMBL15223681 | 0.86 | GLS (0.46) | GLSDGAT1 | |
| SCHEMBL15223706 | 0.83 | DGAT1 (0.40) | GLSDGAT1CYP2C19ALDH1A1LMNA | |
| SCHEMBL12391996 | 0.83 | DGAT1 (0.39) | GLSDGAT1CYP2C19ALDH1A1LMNA | |
| SCHEMBL12391988 | 0.83 | DGAT1 (0.39) | GLSDGAT1CYP2C19ALDH1A1LMNA | |
| SCHEMBL12287268 | 0.82 | SCD (0.44) | GLSDGAT1CYP2C19ALDH1A1LMNA | |
| SCHEMBL12287515 | 0.82 | SCD (0.44) | GLSDGAT1CYP2C19ALDH1A1LMNA | |
| SCHEMBL12452244 | 0.81 | DGAT1 (0.39) | GLSDGAT1MMP2MMP9MMP8 | |
| SCHEMBL12391991 | 0.80 | DGAT1 (0.39) | GLSDGAT1CYP2C19ALDH1A1LMNA | |
| SCHEMBL25514751 | 0.77 | PSMB8 (0.43) | GLSPSMB8PSMB9PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | GLS 991/4885DGAT1 3441/4885MMP2 3272/4885 |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | GLS 991/4885DGAT1 3441/4885MMP2 3272/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | GLS 937/4885DGAT1 3299/4885MMP2 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.